What happens after stopping GLP-1 drugs like Ozempic? Study reveals

A large real-world study finds patients stopping semaglutide or tirzepatide may not regain as much weight as expected, aided by treatment switches, restarts, and lifestyle support

Do you regain all the weight once you stop popular GLP-1 drugs like Ozempic or Mounjaro?

 

A new study titled Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide, published in Diabetes, Obesity and Metabolism, suggests real-world outcomes may be far more encouraging than earlier trials indicated.

 

Analysing nearly 8,000 patients, researchers from Cleveland Clinic, US, found that many people who discontinued these medications did not experience significant weight regain after one year. This is because they often restarted treatment, switched therapies, or adopted lifestyle interventions, changing the trajectory of their weight journey.

 

What are GLP-1 drugs and why are they so popular?

GLP-1 receptor agonists such as semaglutide and tirzepatide are injectable medications used to treat obesity and type 2 diabetes. They work by regulating appetite, slowing gastric emptying, and improving blood sugar control.

 

Their popularity has surged globally due to their effectiveness in producing significant weight loss, often more than traditional approaches. 

What did the study examine about GLP-1 drug discontinuation?

The Cleveland Clinic study tracked 7,938 adults from Ohio and Florida who had:

• Overweight or obesity
• Started semaglutide or tirzepatide
• Discontinued the medication within 3 to 12 months

Researchers then analysed what happened next, both in terms of treatment choices and weight changes over a year.

Do patients regain weight after stopping GLP-1 drugs?

Surprisingly, not as much as earlier clinical trials suggested.

• Patients treated for obesity lost 8.4 per cent of body weight, and regained just 0.5 per cent after one year
• Patients treated for diabetes lost 4.4 per cent, and continued losing an additional 1.3 per cent

This contrasts with earlier trials, where patients regained more than half the lost weight within a year of stopping treatment.

Why are real-world results different from clinical trials?

According to the study authors, the difference lies in what patients do after stopping medication.

 

In real-world settings:

• Many patients restart the same drug
• Others switch to alternative medications
• Some adopt structured lifestyle interventions

These actions help prevent significant weight regain, something not always accounted for in controlled clinical trials. The study also noted that outcomes are not uniform and depend heavily on follow-up care and treatment strategies. 

What do patients do after discontinuing GLP-1 drugs?

The study found that most patients did not abandon treatment altogether. Some switched medications (including older drugs or between GLP-1 options), some restarted their original medication, some opted for lifestyle interventions (dietitians, exercise programmes), some underwent bariatric surgery.

 

This shows that obesity treatment is often a continuous, evolving process rather than a one-time intervention.

Why do people stop taking GLP-1 medications?

Two key reasons emerged:

• Cost and insurance coverage limitations (the most common)
• Side effects

What does this mean for people trying to lose weight?

The findings offer a reassuring message that stopping GLP-1 drugs does not automatically mean regaining all the weight.

 

However, success depends on what comes next, whether it’s restarting medication, switching therapies, or committing to lifestyle changes.

 

The study underscores the importance of ongoing, personalised care in managing obesity as a chronic condition.